Assessing the Adoption of Clinical Trial Results Summary Disclosure to Patients and the Public.

This article discusses why adoption remains low and suggests that the absence of clear regulatory requirements and their enforcement is the primary cause. Expert Commentary: The authors anticipate that the regulatory environment will tighten and that public, patient and patient advocate appetite and expectation for the disclosure of clinical trial results summaries in plain language will intensify during the next 18 months. These pressures will compel research sponsors to accelerate adoption. PMID: 31050914 [PubMed - as supplied by publisher]
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research